Related Experiment Video
Updated: Aug 7, 2026
11:29
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Minimally Invasive Versus Conventional Interval Cytoreduction Surgery for Epithelial Ovarian Carcinoma: A Randomized
Ahmed M Eid1, Osama Hussein1, Mosab S Shetiwy1
1Departments of Surgical Oncology, Faculty of Medicine, Oncology Center, Mansoura University, Mansoura, Egypt.
Indian Journal of Surgical Oncology
|August 6, 2026
Summary
Minimally invasive surgery (MIS) offers shorter operative times and hospital stays for advanced ovarian cancer patients compared to open surgery. Oncologic outcomes, including disease-free survival, remain comparable between both surgical approaches.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Minimally Invasive Surgery
Background:
- Optimal cytoreduction is crucial for survival in advanced epithelial ovarian cancer.
- Minimally invasive surgery (MIS) presents potential perioperative advantages over traditional open surgery.
- Evidence comparing MIS and open surgery for interval cytoreduction post-neoadjuvant chemotherapy is limited.
Purpose of the Study:
- To compare the efficacy and safety of minimally invasive surgery (MIS) versus open surgery for interval cytoreduction in advanced epithelial ovarian cancer patients.
- To evaluate the impact of MIS on perioperative outcomes and long-term oncologic results.
Main Methods:
- A prospective, randomized controlled trial involving 40 women with FIGO stage III-IV epithelial ovarian carcinoma.
- Patients received neoadjuvant chemotherapy and were randomized to undergo either MIS or open interval cytoreduction.
- Primary outcomes included disease-free survival (DFS) and overall survival (OS); secondary outcomes included operative time, blood loss, complications, and hospital stay.
Main Results:
- Minimally invasive surgery (MIS) demonstrated significantly shorter operative times, reduced blood loss, and shorter hospital stays compared to open surgery.
- No significant differences were observed in intraoperative complications, disease-free survival (DFS), or overall survival (OS) between the MIS and open surgery groups.
- Recurrence rates were similar across both surgical approaches.
Conclusions:
- Minimally invasive surgery (MIS) is a safe and feasible option for selected patients with advanced ovarian cancer who respond to neoadjuvant chemotherapy.
- MIS provides significant perioperative benefits without compromising essential oncologic outcomes.
- The findings support the consideration of MIS for interval cytoreduction in advanced ovarian cancer, enhancing patient recovery.
